Halozyme Therapeutics is threatening to drop out of a deal with Baxter International, citing the latter's "manufacturing failures" in making 150U Hylenex, a fluid absorption drug. Halozyme said it is working with the FDA and Baxter to investigate the deficiencies, which have not been linked to adverse events.

Full Story:

Related Summaries